This module enables investors to look at Infinity Pharmaceuticals various fundamental indicators over time in order to gain insight into the company future performance. Macroaxis historical fundamental analysis tools allow evaluation of not only typical financial statement drivers such as Cost of Revenue of 32.5 M, Gross Profit of 18.7 M or Interest Expense of 1.6 M, but also many exotic indicators such as Long Term Debt to Equity of 0.2339, PPandE Turnover of 5.4358 or Receivables Turnover of 1 K. This module is a perfect complement to use when analyzing Infinity Pharmaceuticals Valuation or Volatility. It can also complement various Infinity Pharmaceuticals Technical models. Please also check analysis of Infinity Pharmaceuticals Correlation with competitors.
Showing smoothed Share Based Compensation of Infinity Pharmaceuticals Inc with missing and latest data points interpolated. A component of Net Cash Flow from Operations representing the total amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
|Share Based Compensation||10 Years Trend|
Compare to Other EquitiesAll Fundamental Data
Infinity Pharmaceuticals Share Based Compensation Over Time